Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel

BB Dawood, GC Lowe, M Lordkipanidzé… - Blood, The Journal …, 2012 - ashpublications.org
BB Dawood, GC Lowe, M Lordkipanidzé, D Bem, ME Daly, M Makris, A Mumford, JT Wilde…
Blood, The Journal of the American Society of Hematology, 2012ashpublications.org
Light transmission aggregometry (LTA) is used worldwide for the investigation of heritable
platelet function disorders (PFDs), but interpretation of results is complicated by the
feedback effects of ADP and thromboxane A2 (TxA2) and by the overlap with the response
of healthy volunteers. Over 5 years, we have performed lumi-aggregometry on 9 platelet
agonists in 111 unrelated research participants with suspected PFDs and in 70 healthy
volunteers. Abnormal LTA or ATP secretion test results were identified in 58% of …
Abstract
Light transmission aggregometry (LTA) is used worldwide for the investigation of heritable platelet function disorders (PFDs), but interpretation of results is complicated by the feedback effects of ADP and thromboxane A2 (TxA2) and by the overlap with the response of healthy volunteers. Over 5 years, we have performed lumi-aggregometry on 9 platelet agonists in 111 unrelated research participants with suspected PFDs and in 70 healthy volunteers. Abnormal LTA or ATP secretion test results were identified in 58% of participants. In 84% of these, the patterns of response were consistent with defects in Gi receptor signaling, the TxA2 pathway, and dense granule secretion. Participants with defects in signaling to Gq-coupled receptor agonists and to collagen were also identified. Targeted genotyping identified 3 participants with function-disrupting mutations in the P2Y12 ADP and TxA2 receptors. The results of the present study illustrate that detailed phenotypic analysis using LTA and ATP secretion is a powerful tool for the diagnosis of PFDs. Our data also enable subdivision at the level of platelet-signaling pathways and in some cases to individual receptors. We further demonstrate that most PFDs can be reliably diagnosed using a streamlined panel of key platelet agonists and specified concentrations suitable for testing in most clinical diagnostic laboratories.
ashpublications.org